

David R Wise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8817820/publications.pdf>

Version: 2024-02-01

14
papers

105
citations

1683934

5
h-index

1372474

10
g-index

14
all docs

14
docs citations

14
times ranked

143
citing authors

#	ARTICLE	IF	CITATIONS
1	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1167-1179.	1.5	28
2	Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation. Cancer Treatment and Research Communications, 2020, 25, 100212.	0.7	20
3	Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. European Urology, 2020, 77, 683-686.	0.9	16
4	ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 2021, 39, 5039-5039.	0.8	7
5	Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer. Frontiers in Oncology, 2020, 10, 830.	1.3	6
6	A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 2018, 36, TPS391-TPS391.	0.8	6
7	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	6
8	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. Journal of Clinical Oncology, 2021, 39, 41-41.	0.8	5
9	Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. Journal of Clinical Oncology, 2020, 38, TPS3166-TPS3166.	0.8	4
10	A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 2020, 38, TPS272-TPS272.	0.8	4
11	Somatic and germline sequencing in genitourinary oncology. Current Opinion in Urology, 2019, 29, 315-318.	0.9	2
12	INTREPId (INTERmediate Risk Erection Preservation Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer. Journal of Clinical Oncology, 2020, 38, TPS384-TPS384.	0.8	1
13	Immunosuppressive milieu of high-risk localized prostate cancer. Journal of Clinical Oncology, 2020, 38, 344-344.	0.8	0
14	Germline APC (I1307K) mutation and clinical outcomes in prostate cancer. Journal of Clinical Oncology, 2022, 40, 144-144.	0.8	0